Showing results (841-850 of 6,303) with videos related to
Sort By:
Pageof 631
Diabetes, Obesity & Metabolism|December 5, 2019
Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitusJie Liu, Shrita Patel, Nilo B Cater, et al.Diabetes, Obesity & Metabolism|September 23, 2020
Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trialYing Shuai, Gangyi Yang, Qiu Zhang, et al.Diabetes, Obesity & Metabolism|September 18, 2020
A look to the future in non-alcoholic fatty liver disease: Are glucagon-like peptide-1 analogues or sodium-glucose co-transporter-2 inhibitors the answer?Rebecca K Vincent, David M Williams, Marc EvansDiabetes, Obesity & Metabolism|September 24, 2020
Obesity as a risk factor for COVID-19 mortality in women and men in the UK biobank: Comparisons with influenza/pneumonia and coronary heart diseaseSanne A E Peters, Stephen MacMahon, Mark WoodwardDiabetes, Obesity & Metabolism|September 29, 2020
Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspectiveLinong Ji, Juliana C N Chan, Miao Yu, et al.Diabetes, Obesity & Metabolism|October 1, 2020
Patients with highly unstable type 1 diabetes eligible for islet transplantation can be managed with a closed-loop insulin delivery system: A series of N-of-1 randomized controlled trialsPierre-Yves Benhamou, Sandrine Lablanche, Anne Vambergue, et al.Diabetes, Obesity & Metabolism|October 1, 2020
Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trialsVictor Okunrintemi, Basem M Mishriky, James R Powell, et al.Diabetes, Obesity & Metabolism|October 1, 2020
Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogsUlrich Werner, Norbert Tennagels, Carmine G Fanelli, et al.Diabetes, Obesity & Metabolism|December 15, 2020
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 studyMikhail Kosiborod, Otavio Berwanger, Gary G Koch, et al.Diabetes, Obesity & Metabolism|January 4, 2021
Nonalcoholic fatty liver disease, diastolic dysfunction, and impaired myocardial glucose uptake in patients with type 2 diabetesMinyoung Lee, Kwang Joon Kim, Tae-Ha Chung, et al.Pageof 631